Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Core Insights - Coya Therapeutics has completed patient enrollment for a proof-of-concept study on low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD) [1][2] - The study is progressing without safety issues, with completion anticipated in Q4 2025 [1][2] - The company aims to develop effective treatments for FTD, a neurodegenerative disease with high unmet medical need [3] Study Details - A total of 9 patients have been enrolled in the study, following positive interim results from 5 patients reported earlier [2] - The treatment regimen includes subcutaneous administration of CTLA4-Ig followed by a 5-day course of low-dose IL-2 every four weeks for a total of 22 weeks [1] - No serious adverse events or discontinuations due to safety issues have been reported, indicating a favorable safety profile [2] About Frontotemporal Dementia - FTD is characterized by altered behavior and language, with an estimated 30,000 Americans affected [4] - The average age of onset is 58, with an average survival time of 7.5 years [4] - FTD includes various subtypes, primarily behavioral-variant frontotemporal dementia and two language variants [4] Company Overview - Coya Therapeutics is a clinical-stage biotechnology company focused on developing treatments that enhance regulatory T cell (Treg) function to address systemic inflammation and neuroinflammation [5] - The company’s pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy [6]